![](https://www.pharmavoice.com/imgproxy/2FrjIZJIQnqf1iN-0hJeTx90CKPgLkwjj1aqrghRDpM/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTEyOTMzMDUxODUuanBn.webp)
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
BioNTech found runaway success during the COVID-19 pandemic when its Pfizer-partnered mRNA vaccine propelled the biotech to new heights. But now, with demand for the vaccine substantially lower and revenues way down in the first half of 2024, the pandemic …